Pharmaceutical companies pay close attention to the diabetes drug market, and the research and development of new drugs is accelerating

【Pharmaceutical Network Market Analysis】The field of diabetes treatment has always been one of the hot spots in the global pharmaceutical field, and with the acceleration of the global aging process and the change of people's lifestyle, diabetes patients are increasing day by day, and the drug market is also expanding
.
Data show that the global diabetes drug market in 2020 has reached 69.
7 billion US dollars, under the influence of huge market prospects, strengthening the development of diabetes drugs and improving drug access has now become the focus
of many pharmaceutical companies.
It is reported that since the beginning of this year, a number of domestic new drugs for diabetes have been approved for marketing or clinical trials have made new progress
.
For example, on January 10, Innovent Biopharma announced that the glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist mazdutide (R&D code: IBI362) was a multicenter, randomized, double-blind, placebo-controlled phase III clinical study in subjects with type 2 diabetes in China (DREAMS-1) completed the administration of the first subject
.
It is reported that this phase III clinical study DREAMS-1 will further verify the efficacy and safety
of long-term administration of mazdutide in Chinese patients with type 2 diabetes who do not control diet and exercise alone.
On January 9, Tianyu announced that the company's sitagliptin phosphate API recently passed the technical review
of the Drug Evaluation Center of the State Medical Products Administration.
Sitagliptin phosphate is used for the treatment of type II diabetes, and the company submitted a drug registration application for sitagliptin phosphate API to CDE in January 2020 and was accepted
.
At present, sitagliptin phosphate API has passed the CDE review and approval, but it must obtain the publicity of the GMP compliance inspection result of the Zhejiang Provincial Drug Administration as "meeting the requirements" before it can be marketed
in China.
It is worth mentioning that in order to increase the layout of the diabetes drug market, many companies are currently promoting the clinical development of products under development and the marketing of
listed products through financing.
For example, Sihuan Pharmaceutical recently announced that Huisheng Biotechnology, a non-wholly-owned subsidiary of the Group, has successfully completed the Series A+ financing
conducted by Jilin Baixing Bai Rong Investment Center (Limited Partnership), Jilin Equity Fund Investment Co.
, Ltd.
, Jilin Science and Technology Investment Fund Co.
, Ltd.
and Wuxi Shangwei Venture Capital Partnership (Limited Partnership) as Series A+ investors.
It is reported that the funds of this capital increase will be mainly used for the marketing of listed products of Huisheng Biologics and its subsidiaries, the clinical promotion of products under development, and the replenishment of operating liquidity
。 According to the data, Huisheng Biotech is a biopharmaceutical company focusing on the field of diabetes and complications under Sihuan Pharmaceutical, and currently has more than 40 products in the full product pipeline of diabetes and complications, covering a full range of second-generation, third-generation, fourth-generation insulin and analogue product pipelines (covering basic, premixed and fast-acting products), innovative drug products such as SGLT-2, GLP-1 and other mechanisms of hypoglycemic drugs and complication drugs
。 In general, with the improvement of people's living standards, the prevalence of diabetes is continuing to rise, and the demand for related drugs is also expanding, according to Frost & Sullivan's estimates, China's diabetes drug market size is expected to reach 259.
2 billion yuan
in 2030.
In this context, the market development prospects of related pharmaceutical companies are expected to be very broad
.
However, it should be noted that from the indications of more than 560 domestic drug candidates including diabetes, and GLP-1 (glucagon-like peptide-1 receptor), DPP-4 (dipeptidyl peptidase-4), SGLT-2 (nano-glucose combined transporter-2) and other popular targets are more concentrated, the competition of pharmaceutical companies in this field will be very fierce
in the future.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.